

Supplementary Tables

Table S1. Relation between clinicopathological features and densities of Caveolin-1 and Cavin-1

Variables	Cohort I (n = 69)						Cohort II (n = 84)					
	Caveolin-1		P Value	Cavin-1		P Value	Caveolin-1		P Value	Cavin-1		P Value
	Low (n=34)	High (n=35)		Low (n=34)	High (n=35)		Low (n=42)	High (n=42)		Low (n=42)	High (n=42)	
Age			0.717			0.548			1.000			1.000
≤61 year	16	18		18	16		21	21		21	21	
>61 year	18	17		16	19		21	21		21	21	
Gender			0.404			0.894			0.272			0.272
Female	17	14		15	16		16	21		16	21	
Male	17	21		19	19		26	21		26	21	
CA 19-9			1.000*			0.734*			0.393			0.776
≤27U/ml	4	5		5	4		9	6		8	7	
>27 U/ml	30	30		29	31		33	36		34	35	
Tumor location			0.916			0.387			0.124			0.272
head	19	20		21	18		22	15		21	16	
body,tail	15	15		13	17		20	27		21	26	
Tumor size			0.925			0.687			0.127			0.827
≤ 5 cm	21	22		22	21		25	18		22	21	
> 5 cm	13	13		12	14		17	24		20	21	
Lymph node metastasis			0.012			0.041			0.002			0.027
No	21	11		20	12		25	11		23	13	
Yes	13	24		14	23		17	31		19	29	
Neural invasion			0.477*			1.000*			0.776			0.393
No	3	6		4	5		8	7		6	9	
Yes	31	29		30	30		34	35		36	33	
Microvascular invasion			0.650			0.650			0.620			0.136
No	25	24		25	24		32	30		34	28	
Yes	9	11		9	11		10	12		8	14	
Tumor differentiation			0.921			0.170			0.118			0.503
Low	20	21		23	18		29	22		27	24	
High	14	14		11	17		13	20		15	18	
TNM stage			0.031*			0.122*			0.006			0.071
IB	4	1		3	2		11	3		8	6	
IIA	17	10		17	10		14	8		15	7	
IIB	13	24		14	23		17	31		19	29	
Cavin-1			0.003			/			0.001			/
Low	23	11		/	/		30	12		/	/	
High	11	24		/	/		12	30		/	/	
Cavin-2			0.906			0.118			0.190			0.081
Low	17	17		20	14		24	18		25	17	
High	17	18		14	21		18	24		17	25	
Cavin-3			0.548			0.717			0.663			0.383
Low	18	16		16	18		20	22		23	19	
High	16	19		18	17		22	20		19	23	

CA 19-9, carbohydrate antigen 19-9

* The expected frequencies in the cells (more than 25%) are less than 5.0, Fisher's exact test was adopted

Table S2. Univariate and multivariate analyses of factors associated with survival and recurrence

Variables	Cohort I (n = 69)								Cohort II (n = 84)							
	Overall Survival				Time to Recurrence				Overall Survival				Time to Recurrence			
	Univariate		Multivariate		Univariate		Multivariate		Univariate		Multivariate		Univariate		Multivariate	
	<i>P</i> value		<i>P</i> value		<i>P</i> value		<i>P</i> value		<i>P</i> value		<i>P</i> value		<i>P</i> value		<i>P</i> value	
	<i>P</i> value	HR	95% CI	<i>P</i> Value	<i>P</i> value	HR	95% CI	<i>P</i> value	<i>P</i> value	HR	95% CI	<i>P</i> Value	<i>P</i> value	HR	95% CI	<i>P</i> value
Age (≤61 year / >61 year)	0.239			NA	0.154			NA	0.162			NA	0.600			NA
Gender (male/female)	0.645			NA	0.999			NA	0.160			NA	0.146			NA
CA 19-9 (≤27 U/ml / >27 U/ml)	0.702			NA	0.288			NA	0.070			NA	0.403			NA
Tumor location (head/body, tail)	0.768			NA	0.633			NA	0.166			NA	0.072			NA
Tumor size (≤ 5 cm / > 5 cm)	0.486			NA	0.528			NA	0.502			NA	0.937			NA
Lymph node metastasis (yes/no)	0.011			NS	0.004			NS	0.003			NS	0.003			NS
Tumor differentiation (I-II/III-IV)	0.393			NA	0.183			NA	0.078			NA	0.086			NA
Neural invasion (yes/no)	0.500			NA	0.574			NA	0.568			NA	0.590			NA
Microvascular invasion (yes/no)	0.162			NA	0.168			NA	0.380			NA	0.319			NA
TNM stage (IB/IIA/IIB)	0.029	1.800	1.088 - 2.977	0.022	0.006	1.962	1.279 - 3.011	0.002	0.011	1.735	1.058 - 2.846	0.029	0.004	1.742	1.155 - 2.628	0.004
Caveolin-1	0.010	1.924	1.071 - 3.457	0.029	0.033	1.733	1.029 - 2.918	0.039	0.002	2.334	1.160 - 4.697	0.017	0.004	1.786	1.009 - 3.161	0.046
Cavin-1	0.058			NA	0.066			NA	0.096			NA	0.065			NA
Combined Caveolin-1 and Cavin-1*	0.001			NA	0.002			NA	0.001			NA	< 0.001			NA
Cavin-2	0.590			NA	0.806			NA	0.829			NA	0.748			NA
Combined Caveolin-1 and Cavin-2	0.053			NA	0.189			NA	0.018			NA	0.040			NA
Cavin-3	0.478			NA	0.934			NA	0.801			NA	0.431			NA
Combined Caveolin-1 and Cavin-3	0.054			NA	0.059			NA	0.019			NA	0.026			NA

CA 19-9, carbohydrate antigen 19-9; HR, hazard ratio; CI, Confidence interval; NA, not adopted; NS, not significant

* Patients were classified into four groups according to Caveolin-1 and Cavin-1 density in the cohort 1: group I (n = 23), both low density; group II (n = 11), high Caveolin-1 but low Cavin-1; group III (n = 11), low Caveolin-1 but high Cavin-1 density; and group IV (n = 24), both high density; and in the cohort 2: group I (n = 30), both low density; group II (n = 12), high Caveolin-1 but low Cavin-1 density; group III (n = 12), low Caveolin-1 but high Cavin-1 density; and group IV (n = 30), both high density.

Table S3. Clinicopathological features of patients from the Cohort I and II

Features	Cohort I (n =69)	Cohort II (n = 84)
	Values/Counts	Values/Counts
Age (years, median (range))	62 (33-76)	62 (35-83)
Gender (male/female)	38/31	47/37
CA 19-9 (U/ml, median (range))	232.6 (0.8->2011)	202.0 (1.4->2011)
Tumor location (head/body, tail)	39/30	37/47
Tumor size (cm, mean $\pm$ SD)	4.9 $\pm$ 1.7	5.6 $\pm$ 1.8
Lymph node metastasis (yes/no)	37/32	48/36
Tumor differentiation (I-II/III-IV)	41/28	51/33
Neural invasion (yes/no)	60/9	69/15
Microvascular invasion (yes/no)	20/49	22/62
TNM stage (IB/IIA/IIB)	5/27/37	14/12/48

CA 19-9, carbohydrate antigen 19-9